Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Operating Expenses: 2009-2024

Historic Operating Expenses for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Dec 2024 value amounting to $258.3 million.

  • Ironwood Pharmaceuticals' Operating Expenses fell 29.38% to $46.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.8 million, marking a year-over-year decrease of 22.71%. This contributed to the annual value of $258.3 million for FY2024, which is 81.39% down from last year.
  • According to the latest figures from FY2024, Ironwood Pharmaceuticals' Operating Expenses is $258.3 million, which was down 81.39% from $1.4 billion recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Operating Expenses ranged from a high of $1.4 billion in FY2023 and a low of $160.3 million during FY2022.
  • Over the past 3 years, Ironwood Pharmaceuticals' median Operating Expenses value was $258.3 million (recorded in 2024), while the average stood at $602.2 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Operating Expenses spiked by 766.20% in 2023 and then plummeted by 81.39% in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Operating Expenses (Yearly) stood at $246.6 million in 2020, then decreased by 26.40% to $181.5 million in 2021, then dropped by 11.70% to $160.3 million in 2022, then soared by 766.20% to $1.4 billion in 2023, then plummeted by 81.39% to $258.3 million in 2024.